China
Africa
Explore chapters and articles related to this topic
Plant-Based Adjunct Therapy for Tuberculosis
Published in Namrita Lall, Medicinal Plants for Cosmetics, Health and Diseases, 2022
Lydia Gibango, Anna-Mari Reid, Jonathan L. Seaman, Namrita Lall
South African medicinal plants such as Pelargonium sidoides DC. and Pelargonium reniforme Curtis are traditionally used as infusions made from their tuberous, woody roots. Pelargonium sidoides DC. has a long history of use for medicinal purposes and for tuberculosis in particular. In 1897, an Englishman named Charles Henry Stevens who was suffering from tuberculosis was advised by his doctor to go to South Africa to cure the disease. In what is known as Lesotho today, he met Kagaitse, a Zulu man who was an expert on medicinal plants, and was given a boiled root preparation of the plant. After three months of treatment, Stevens was cured of tuberculosis (Bladt and Wagner, 2007). This plant, native to South Africa, was then taken to England by Stevens where today, the extract of the plant is sold all over Europe. In South Africa, it has long been used by the Zulu people to treat diarrhea, dysentery and gonorrhea (Drewes, 2012).
Infectious Disease: Upper Respiratory Infections and Otitis Media
Published in Hilary McClafferty, Integrative Pediatrics, 2017
A 2008 Cochrane Database Systematic Review found that Pelargonium sidoides, a homeopathic preparation derived from the medicinal plant, may have some efficacy in improving symptoms of URI in children, although mechanism is not well understood (Timmer et al. 2008).
Traditional Medicine Situation in Africa
Published in Charles Wambebe, African Indigenous Medical Knowledge and Human Health, 2018
Ossy MJ Kasilo, Jean-Baptiste Nikiema, Abayneh Desta, André Lona
The Egyptian Pharmacopoeia (1972, 1980) is the national pharmacopoeia that contains monographs on herbal medicines, and it is legally binding (WHO, 2005a, b, c). In lieu of a national pharmacopoeia, Sudan uses the British Herbal Pharmacopoeia, and it is considered to be legally binding, and in place of national monographs, the WHO Monographs are used (WHO, 2005a, b, c). Ghana published the second edition of its National Herbal Pharmacopoeia (The Government of Ghana, 2007), whereas Nigeria (The Government of Nigeria, 2008) and the Democratic Republic of the Congo (Ministry of Health, 2009: 1) printed the first editions of their national herbal pharmacopoeias in 2008 and 2009, respectively. Benin developed 418 monographs of medicinal plants used for the treatment of uncomplicated malaria during 2009–2014. The country also developed 304 monographs of medicinal plants used for the treatment of opportunistic infections of HIV/AIDS with support from the African Development Bank (ADB) (WHO, 2015). Similarly, experts of the Association for African Medicinal Plants Standards (AAMPS), founded in 2005 to support the African herbal industry and regulatory authorities by developing quality control and quality assurance standards for African medicinal plants and herbal medicines, published the African Herbal Pharmacopoeia (AAMPS, 2010: 1). This pharmacopoeia has monographs on 51 selected African medicinal plants, including well-known examples such as Catharanthus roseus, Prunus africana, Harpagophytum procumbens, Pelargonium sidoides, and the South African cancer bush, Sutherlandia frutescens.
HL301 versus Umckamin in the treatment of acute bronchitis: a phase III, randomized, controlled, double-blind, multicenter study
Published in Current Medical Research and Opinion, 2020
Won-Young Kim, Myung Jae Park, Chin Kook Rhee, Sang Yeub Lee, Do Jin Kim, Dong Gyu Kim, Chang-Min Choi, Deog Kyeom Kim, Yee Hyung Kim, Ho Joo Yoon, Jae Yeol Kim
Pelargonium sidoides is a perennial plant found in different locations in South Africa. Traditionally, the plant material was used for treating common cold and cough. Its aqueous-ethanolic root extract, Umckamin is approved for the treatment of acute bronchitis and is widely used for treating acute and chronic respiratory tract infections14,15. It has many pharmacologic effects, especially antibacterial, as well as antiviral and immunomodulatory activities16,17. Although doubt exists, P sidoides was effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults. Given that it is one of the rare herb extracts with effects that have been proven by multiple, well-designed, randomized, controlled trials, it was selected as an active comparator of HL301. We did not include a placebo arm in the present study because HL301 was proved to be more effective in the symptomatic treatment of acute bronchitis than placebo in the previous two studies7,8.
Effects of Pelargonium sidoides extract on chemokine levels in nasal secretions of patients with non-purulent acute rhinosinusitis
Published in Journal of Drug Assessment, 2020
Aleksandar Perić, Sandra Vezmar Kovačević, Aleksandra Barać, Dejan Gaćeša, Aneta V. Perić, Danilo Vojvodić
Traditionally, herbal medicines have been used for centuries for therapy of acute upper airway infections. Herbal preparation from the roots of Pelargonium sidoides was used for generations in South Africa for treatment of respiratory and gastrointestinal infections, due to its antiviral and antibacterial actions5. More than seven decades later, this polyphenol-rich extract was finally developed in Germany with coding name EPs 76306,7,i. According to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 and International Consensus treatment on Allergy & Rhinology: Rhinosinusitis, the use of EPs 7630 is recommended as an option in therapy of ARS3,8. The immunomodulatory effects of this herbal drug are mediated mainly by stimulation of tumor necrosis factor alpha (TNF-α), interferon beta (IFN-β), IFN-γ and interleukin-10 (IL-10) production and reducing production of IL-6 and IL-15 in human respiratory tract epithelial cells5–7,9,10. Intensity of inflammatory reaction during the ARS depends on attraction of inflammatory cells. Chemokines are small cytokines that attract different inflammatory cells to the site of inflammation. However, in vivo studies related to the effects of EPs 7630 on chemokine production in nasal mucosa of patients with ARS were not previously conducted. This study was designed to compare the chemokine production in nasal mucosa of participants with and without APRS and to assess the effects of EPs 7630 on chemokine release in nasal secretions of patients with this uncomplicated form of ARS.
EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited
Published in Current Medical Research and Opinion, 2018
Wolfgang Kamin, Petra Funk, Georg Seifert, Andrea Zimmermann, Walter Lehmacher
Eligible studies had to be clinical trials or non-interventional investigations assessing treatment with EPs 7630, a herbal drug preparation from the roots of Pelargonium sidoides (1:8–10), extraction solvent: ethanol 11% (w/w), in otherwise healthy patients suffering from an aRTI (ATP, ARS, AB, ARP) or from an exacerbation of a recurrent aRTI, and which included children under the age of 6 years. Searches were performed during March 2016 (MEDLINE, EMBASE; search terms “EPs 7630” or “Umckaloabo”, in combination with “children” and “clinical study” or “clinical trial” without further restrictions). Additional information was obtained from the manufacturer of EPs 7630.